Erratum to: Oncol Ther DOI 10.1007/s40487-016-0016-0

The author of the above mentioned paper have noticed a mistake in Table 1 following publication and wish to make the following correction.

The reference for the lapatinib study should be 36 (Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24:1931–6), and the reference for the 9-nitro-camptothecin study should be 43 (Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597–604).

The corrected Table 1 can be found below.

Table 1 Summary of systemic therapy data